Contents

Foreword xv

Preface xix

Summary points and recommendations xix

Background xxii

Background to the second edition xxii

Background to the first edition xxvi

The changing regulatory environment xxvii

Introduction xxx

More education rather than more regulation xxx

The need to identify investment risk xxxi

Target readership xxxiii

Commercial benefits to compliance xxxiii

Local differences and specific circumstances xxxiv

Summary xxxiv

Case studies and examples xxxv

Themes xxxvii

Research coverage xxxvii

Sourcing information xxxviii

Reasonable basis for recommendations and risk assessment xxxix

Conflicts of interest xl

Writing in general xli

Acknowledgments xlv

Abbreviations Used in This Book xlvii

Chapter 1: Principles of Research 1

Key points 2

Definition and supervision of research 2

Supervision and control of research 2

Marketing research to the U.S. by foreign broker-dealers 3

Stock-picking tips 8

Continuing education 9

Cheating in tests 10

The realm of research 11

Ambit of securities regulations (bonds) 12

Ambit of securities research regulations (equity and credit research analysts) 13

Ambit of securities regulations (swaps and other derivatives) 16
Ambit of securities research regulations
(marketers of research, including hedge fund research) 19
Ambit of securities research regulations
(analysts as experts on sales desks) 20
Ambit of securities research regulations
(stock-tipping bloggers) 21
Ambit of securities research regulations
(media commentators) 23
Minimizing approval and publishing risks 26
Honesty and fair treatment of clients 28
Common securities-related violations cited by the SEC and FINRA of the U.S. 28
Regulations tightening up around the world (Hong Kong) 29
Regulations tightening up around the world (China) 31
Regulations tightening up around the world (Japan) 32
Front-running and selective distribution of research 35
Front-running and selective distribution of research (huddles) 35
Front-running of research 36
Selective distribution of research 37
Selective distribution of research (fact-checking) 39
Selective distribution of research (greater conviction of view) 39
Insider dealing and selective disclosure 41
Use/dissemination of price-sensitive information (general) 44
Use/dissemination of price-sensitive information (U.S.) 47
Use/dissemination of price-sensitive information (U.K.) 48
Use/dissemination of price-sensitive information (Hong Kong) 50
Use/dissemination of price-sensitive information
(serial insider trading) 53
Use/dissemination of price-sensitive information (pillow talk) 54
Use/dissemination of price-sensitive information (economists) 56
Specific requests and proprietary information 58
Definition of publishing 59
Unfair portrayal of past recommendations 60
Performance of past recommendations 60
Conflicts of interest and disclosure of interests 62
Catering to investors with specific investment criteria 62
Shari‘ah law implications for securities research
analysts (stocks) 64
Shari‘ah law implications for securities research
analysts (bonds) 65
The virtues of a vice portfolio 67
Analyst surveys 67
Playing the voting “game” 68
Sourcing information 71
Acknowledging the source 71
Gathering confidential information 72
Receiving confidential information 76
Contents

Rumors, speculation and M&A 79
Identifying M&A candidates (putting companies into play) 81
Short selling by hedge funds (abusive rumor-mongering) 84
Defamation—libel and slander 88
Defamation 89
Intellectual property—copyright and plagiarism 91
Intellectual property 91
Research integrity and consistency 95
The problem 95
Disgruntled clients 95
The principles 96
. . . be consistent or explain apparent inconsistencies 97
Sector/country weightings and universes 100
Consistency of views 101
Top picks (research requirements) 102
Consistency of views 104
Technical analysis 105
Useful qualifications (technical analysis) 106
Coverage universe—initiations, terminations and transfers 106
Accountability principles 106
Initiation of coverage 107
Transfer or re-initiation of coverage 107
Co-authorship liability 108
Termination of coverage 109
“Under review” 110
Publishing new research 111
No recommendation? 111
No recommendations 114

Chapter 2: Reasonable Basis, Valuations and Risk 119
Key points 120
Consistency of recommendations 121
Explanation for inconsistencies 121
Following the market 122
Valuation support 122
Forensic analysis of accounts 122
Channel-stuffing and other activities 123
Cross-industry antitrust issues 124
Disclosures and notes 126
Pro-forma accounting and use of selective data 128
Reasonableness of valuations 128
Highlight valuation changes 129
The appropriate valuation methodology 129
Unrealistic expectations or questionable bases for valuation 130
Excessive valuations 132
Highlighting risks and volatility 133
Appropriateness of sell ratings 134
Short-selling by hedge funds (pushing the envelope?) 135
Management’s reaction to negative research (legal action) 137
Management’s reaction to negative research (restricting information) 138
Mis-selling and not highlighting risks 139
   Highlighting investment risks (credit crisis of 2007/08, U.S.) 139
   Highlighting investment risks (credit crisis of 2007/08, global) 142
   Highlighting investment risks (general) 144
Evaluating risks and catalysts 146
   Catalysts and consensus 147
Market liquidity and contagion risks 147
Foreign exchange and interest rate risks 147
   Currency risks 148
Earnings risks 150
Brand theft risk 151
   Brand theft 151
   Brand usurping 152
Cashflow and liquidity risks 153
Valuation risks 153
Modeling and miscalculation risks 154
   Modeling risks 155
   Mispricing risks 156
Information risk 157
M&A risks 158
Corporate governance risks 159
Gauging corporate governance risks 159
   Social responsibility 161
      Corporate governance (social responsibility—rankings) 161
      Durability of brand names 163
      Corporate governance (social responsibility—the mass-consumer market) 164
      Corporate governance (social responsibility—corporate governance excellence) 165
   Executive remuneration 167
      Corporate governance (executive remuneration) 168
      Corporate governance (executive remuneration—disclosures) 172
   Executive insider trading 174
      Corporate governance (executive insider trading) 175
   Equal treatment of shareholders 176
      Corporate governance (equal treatment of shareholders) 177
      Corporate governance (related-party transactions) 179
      Corporate governance (equal treatment of shareholders—related-party transactions) 181
      Corporate governance (vote manipulation) 182
      Corporate governance (independent non-executive directors) 184
   National interest 184
      Corporate governance (national interest) 184
      Corporate governance (national interest—strategic industries) 187
Corporate governance (national interest—sovereign wealth funds) 189
Risk management 189
Corporate governance (false statements by issuers) 190
Corporate governance (risk management and rogue traders) 191
Corporate governance (transparency of operations) 196
Ponzi schemes 197
Corporate governance (risk management and money-laundering, bribery and corruption) 199
Credit rating risks 201
Analyzing risk (credit rating agencies) 201
Due diligence by investment bankers 203
Due diligence (failures) 204

Chapter 3: Independence of Research and Conflicts of Interest 209
Key points 210
Summary 210
Separating research and banking 211
  Conflicts of interest (global settlements) 212
  Conflicts of interest (collateralized debt obligations) 214
  Conflicts of interest (auction-rate securities) 216
Managing contacts between analysts and bankers 217
Disclosures of interests and relationships 219
  Conflicts of interest (private trading contrary to recommendations) 220
  Analyst certification 221
  Conflicts of interest (disclosures) 222
Writing research on banking clients 223
  Conflicts of interest (watch lists) 225
  Conflicts of interest (managing apparent conflicts) 226
“Pre-deal” research 230
  Conflicts of interest (pre-deal research) 231
Influencing of analysts by issuers 234
  Conflicts of interest (bribes) 234
  Conflicts of interest (favors) 235
  Conflicts of interest (issuers guiding analysts) 236
  Conflicts of interest (employment) 237
Independent research firms 238
  Alleged conflicts of interest (independent research firms) 239
Paying for sell-side research 242
  Transparency in paying for research (inappropriate payments) 245
  Paying for credit ratings 246

Chapter 4: Non-research: E-mails, Blogs and Internal Communications 251
Key points 252
  Approval of e-mail and media appearances 253
Objective commentary on non-rated companies 254
E-mails 256
   E-mails as research 257
   Retention of e-mails 259
   “Internal Use Only” 261

Chapter 5: General Writing, Editing and Publishing Considerations 263
Key points 264
Introduction 264
Getting the message across 265
   Headlines and covers 265
      Standards of taste 266
   Bullets, key points and executive summaries 267
   Publishing and distribution 267
Writing the text 268
   Writing rules 268
Use the right word 269
   Vocabulary for attributing forward-looking comments (using “will”) 269
Measurements and direction/degree of movement 271
   Vocabulary for describing movement and performance 272
Words to avoid or use carefully 273
   Bullshit Bingo (vocabulary and phrases) 274
   Clarity of communication 275
Clarity, consistency, conformity and continuity 276
   Be consistent or explain inconsistencies 277
   Editorial departments and style guides 277
Translations into different languages 278
   Mistranslations 278
Publishing independent yet integrated reports 279
   Sensitivity to politics and religion 280
      Sensitivity to politics and religion 280
Correcting errors 281
   Courses of corrective action 281
Materiality of the error 282
   Publishing of out-of-date story 282
   Retractions 283
   Helping the reader 286

Index 287